Silence Therapeutics (SLN) EBIAT (2019 - 2025)
Historic EBIAT for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to -$21.0 million.
- Silence Therapeutics' EBIAT rose 4651.43% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 2320.54%. This contributed to the annual value of -$45.3 million for FY2024, which is 1569.14% up from last year.
- Per Silence Therapeutics' latest filing, its EBIAT stood at -$21.0 million for Q3 2025, which was up 4651.43% from -$27.4 million recorded in Q2 2025.
- Silence Therapeutics' 5-year EBIAT high stood at $12.3 million for Q4 2024, and its period low was -$39.2 million during Q3 2024.
- Moreover, its 5-year median value for EBIAT was -$16.6 million (2021), whereas its average is -$16.5 million.
- As far as peak fluctuations go, Silence Therapeutics' EBIAT soared by 16622.85% in 2024, and later tumbled by 56837.47% in 2025.
- Quarter analysis of 5 years shows Silence Therapeutics' EBIAT stood at -$15.1 million in 2021, then dropped by 16.64% to -$17.7 million in 2022, then decreased by 5.23% to -$18.6 million in 2023, then surged by 166.23% to $12.3 million in 2024, then tumbled by 270.36% to -$21.0 million in 2025.
- Its EBIAT stands at -$21.0 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$28.5 million for Q1 2025.